Reipet – Lifestyle
Author:
Alpha Tau Medical Ltd.
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
April 23, 2026
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
April 23, 2026
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
March 31, 2026
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
March 16, 2026
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
March 9, 2026